
The S&P/ASX 200 Index (ASX: XJO) was out of form last week and dropped lower. The benchmark index fell 0.6% to end the week at 6,715.4 points.
Fortunately, not all shares dropped lower with the market. Here’s why these were the best performing ASX 200 shares last week:
Pro Medicus Limited (ASX: PME)
The Pro Medicus share price was the best performer on the ASX 200 last week with a massive gain of 17.1%. Investors were buying the health imaging software company’s shares after it announced another major new contract win. Pro Medicus has signed a seven-year contract worth $40 million with Salt Lake City based Intermountain Healthcare. The deal will see its Visage 7 Viewer and Visage 7 Open Archive products implemented across all of Intermountain’s radiology and subspecialty imaging departments. This is its fifth major contract win in the space of six months.
Afterpay Ltd (ASX: APT)
The Afterpay share price wasn’t far behind with a 14.8% gain over the five days. Bullish sentiment in the buy now pay later sector following Affirm’s IPO in the US and a positive broker note out of Morgan Stanley gave its shares a boost. In respect to the latter, Morgan Stanley retained its overweight rating and lifted its price target on the payments company’s shares to $136.00. The broker points out that app downloads have been increasing strongly in the US and UK. It is expecting Afterpay to report 13.6 million active customers for the first half of FY 2021. This will be a 37.4% increase from 9.9 million active customers at the end of FY 2020.
Whitehaven Coal Ltd (ASX: WHC)
The Whitehaven Coal share price was on form last week and recorded a sizeable 13% gain. This followed the release of its quarterly update, which reaveled that Whitehaven Coal achieved a 64% increase in managed run-of-mine (ROM) production to 5.1Mt for the three months ended 31 December. And while its sales were flat on the prior corresponding period, management has tightened its sales guidance range to between 19Mt and 20Mt from 18.5Mt and 20Mt. The company also revealed that coal prices have been improving strongly.
Mesoblast limited (ASX: MSB)
The Mesoblast share price returned to form at last and jumped 9.4% over the five days. Investors were buying the biotech company’s shares after it finally released a positive announcement. Mesoblast announced that its rexlemestrocel-L drug provides a reduction in heart attacks, strokes, and cardiac death in patients with chronic heart failure. According to the study, heart attacks and strokes were reduced by 60% from a single dose.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting…
Because ‘Doc’ Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
See how you can find out the name of this stock
Returns as of 6th October 2020
More reading
- These were the worst performing ASX 200 shares last week
- ASX 200 ends flat on Friday
- What’s in store for the ASX tech sector in 2021?
- Singular Health IPO, another medical imaging contender?
- Pro Medicus (ASX:PME) share price hits record high: Is it too late to invest?
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of AFTERPAY T FPO. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post These were the best performing ASX 200 shares last week appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/3iecG48
Leave a Reply